Biodesix company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biodesix.com

Founded Year

2005

Stage

IPO | IPO

Total Raised

$259.21M

Date of IPO

10/28/2020

Market Cap

0.07B

Stock Price

1.60

About Biodesix

Biodesix (NASDAQ: BDSX) is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix develops, validates, and commercializes VeriStrat, a serum proteomic test currently available to help physicians guide therapy for patients with advanced non-small-cell lung cancer.

Biodesix Headquarter Location

2970 Wilderness Place Suite 100

Boulder, Colorado, 80301,

United States

303-417-0500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biodesix

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biodesix in 2 CB Insights research briefs, most recently on Mar 12, 2020.

Expert Collections containing Biodesix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biodesix is included in 5 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

7,911 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

H

Health IT

7,900 items

Biodesix Patents

Biodesix has filed 51 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Classification algorithms
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2017

12/7/2021

Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes

Grant

Application Date

8/18/2017

Grant Date

12/7/2021

Title

Related Topics

Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes

Status

Grant

Biodesix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biodesix Rank

You May Also Like

P
ProteoGenix

ProteoGenix offers maternal-fetal diagnostics

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

H
Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.

A
AngioLogix

AngioLogix is a provider of cardiovascular health diagnostics.

L
Labnow

LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.